B3GNT5 Polyclonal antibody
B3GNT5 Polyclonal Antibody for WB, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IHC, ELISA
Conjugate
Unconjugated
Cat no : 20422-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | mouse lung tissue, MCF-7 cells |
| Positive IHC detected in | human lung tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:3000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 2 publications below |
| IHC | See 2 publications below |
Product Information
20422-1-AP targets B3GNT5 in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | B3GNT5 fusion protein Ag14246 相同性解析による交差性が予測される生物種 |
| Full Name | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 |
| Calculated molecular weight | 378 aa, 44 kDa |
| Observed molecular weight | 44 kDa |
| GenBank accession number | BC028058 |
| Gene symbol | B3GNT5 |
| Gene ID (NCBI) | 84002 |
| RRID | AB_10694280 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
B3GNT5 (UDP-GlcNAc:β-Gal β-1,3-N-acetylglucosaminyltransferase 5) is a glycosyltransferase that transfers an N-acetylglucosamine (GlcNAc) from uridine diphosphate (UDP)-GlcNAc to galactose at the nonreducing end of carbohydrate chain. B3GNT5 is required for tumorigenicity of breast cancer and glycosylation of B3GNT5 is critical for its protein stabilization (PMID: 35526049). B3GNT5 was highly expressed in human GBM and glioma cell lines in culture, and was associated with poor patient survival (PMID: 32677340). B3GNT5 was N-glycosylated, and glycosylation of B3GNT5 stabilized its protein for non-glycosylated B3GNT5 protein degraded more rapidly than glycosylated form (PMID: 35526049).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for B3GNT5 antibody 20422-1-AP | Download protocol |
| IHC protocol for B3GNT5 antibody 20422-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
J Cell Mol Med MiR-30a-5p inhibits proliferation and metastasis of hydatidiform mole by regulating B3GNT5 through ERK/AKT pathways. | ||
Cell Rep Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins | ||
iScience B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer
|
